Activation of Rho GTPase Cdc42 Promotes Adhesion and Invasion in Colorectal Cancer Cells

Overview

Journal Med Sci Monit Basic Res

Specialty Biotechnology

Date 2013 Jul 26

PMID 23884297

Citations 20

Authors

Lei Gao

Lan Bai

Qing zhen Nan

Affiliations

Soon will be listed here.

Abstract

Background: The purpose of this study was to investigate the role of activated Rho GTPase cell division control protein 42 homolog (Cdc42) in colorectal cancer cell adhesion, migration, and invasion.

Material And Methods: The constitutively active form of Cdc42 (GFP-Cdc42L61) or control vector was overexpressed in the colorectal cancer cell line SW480. The localization of active Cdc42 was monitored by immunofluorescence staining, and the effects of active Cdc42 on cell migration and invasion were examined using an attachment assay, a wound healing assay, and a Matrigel migration assay in vitro.

Results: Immunofluorescence staining revealed that constitutively active Cdc42 predominately localized to the plasma membrane. Compared to SW480 cells transfected with the control vector, overexpression of constitutively active Cdc42 in SW480 cells promoted filopodia formation and cell stretch and dramatically enhanced cell adhesion to the coated plates. The wound healing assay revealed a significant increase of migration capability in SW480 cells expressing active Cdc42 compared to the control cells. Additionally, the Matrigel invasion assay demonstrated that active Cdc42 significantly promoted SW480 cell migration through the chamber.

Conclusions: Our results suggest that active Rho GTPase Cdc42 can greatly enhance colorectal cancer cell SW480 to spread, migrate, and invade, which may contribute to colorectal cancer metastasis.

Citing Articles

Probing the diabetes and colorectal cancer relationship using gene - environment interaction analyses.

Dimou N, Kim A, Flanagan O, Murphy N, Diez-Obrero V, Shcherbina A Br J Cancer. 2023; 129(3):511-520.

PMID: 37365285 PMC: 10403521. DOI: 10.1038/s41416-023-02312-z.

The relation of blood cell division control protein 42 level with disease risk, comorbidity, tumor features/markers, and prognosis in colorectal cancer patients.

Gao S, Xue J, Wu X, Zhong T, Zhang Y, Li S J Clin Lab Anal. 2022; 36(7):e24572.

PMID: 35735582 PMC: 9279954. DOI: 10.1002/jcla.24572.

Rho GTPases as Key Molecular Players within Intestinal Mucosa and GI Diseases.

Pradhan R, Ngo P, Martinez-Sanchez L, Neurath M, Lopez-Posadas R Cells. 2021; 10(1).

PMID: 33406731 PMC: 7823293. DOI: 10.3390/cells10010066.

Vimentin immunoexpression is associated with higher tumor grade, metastasis, and shorter survival in colorectal cancer.

Al-Maghrabi J Int J Clin Exp Pathol. 2020; 13(3):493-500.

PMID: 32269687 PMC: 7137029.

Drugging the Small GTPase Pathways in Cancer Treatment: Promises and Challenges.

Prieto-Dominguez N, Parnell C, Teng Y Cells. 2019; 8(3).

PMID: 30884855 PMC: 6468615. DOI: 10.3390/cells8030255.

References

Bouzahzah B, Albanese C, Ahmed F, Pixley F, Lisanti M, Segall J . Rho family GTPases regulate mammary epithelium cell growth and metastasis through distinguishable pathways. Mol Med. 2002; 7(12):816-30. PMC: 1950008. View

Jung I, Lee J, Yun S, Park C, Choi W, Lee H . Cdc42 and Rac1 are necessary for autotaxin-induced tumor cell motility in A2058 melanoma cells. FEBS Lett. 2002; 532(3):351-6. DOI: 10.1016/s0014-5793(02)03698-0. View

Jaffe T, Schwartz B . Leptin promotes motility and invasiveness in human colon cancer cells by activating multiple signal-transduction pathways. Int J Cancer. 2008; 123(11):2543-56. DOI: 10.1002/ijc.23821. View

Wang L, Zheng Y . Cell type-specific functions of Rho GTPases revealed by gene targeting in mice. Trends Cell Biol. 2006; 17(2):58-64. DOI: 10.1016/j.tcb.2006.11.009. View

Moon S, Zheng Y . Rho GTPase-activating proteins in cell regulation. Trends Cell Biol. 2002; 13(1):13-22. DOI: 10.1016/s0962-8924(02)00004-1. View

Bishop A, Hall A . Rho GTPases and their effector proteins. Biochem J. 2000; 348 Pt 2:241-55. PMC: 1221060. View

Parri M, Chiarugi P . Rac and Rho GTPases in cancer cell motility control. Cell Commun Signal. 2010; 8:23. PMC: 2941746. DOI: 10.1186/1478-811X-8-23. View

Gomez del Pulgar T, Valdes-Mora F, Bandres E, Perez-Palacios R, Espina C, Cejas P . Cdc42 is highly expressed in colorectal adenocarcinoma and downregulates ID4 through an epigenetic mechanism. Int J Oncol. 2008; 33(1):185-93. View

Nobes C, Hall A . Rho, rac, and cdc42 GTPases regulate the assembly of multimolecular focal complexes associated with actin stress fibers, lamellipodia, and filopodia. Cell. 1995; 81(1):53-62. DOI: 10.1016/0092-8674(95)90370-4. View

10.

Rossman K, Der C, Sondek J . GEF means go: turning on RHO GTPases with guanine nucleotide-exchange factors. Nat Rev Mol Cell Biol. 2005; 6(2):167-80. DOI: 10.1038/nrm1587. View

11.

Jaffe A, Hall A . Rho GTPases: biochemistry and biology. Annu Rev Cell Dev Biol. 2005; 21:247-69. DOI: 10.1146/annurev.cellbio.21.020604.150721. View

12.

Zohrabian V, Forzani B, Chau Z, Murali R, Jhanwar-Uniyal M . Rho/ROCK and MAPK signaling pathways are involved in glioblastoma cell migration and proliferation. Anticancer Res. 2009; 29(1):119-23. View

13.

Szczur K, Xu H, Atkinson S, Zheng Y, Filippi M . Rho GTPase CDC42 regulates directionality and random movement via distinct MAPK pathways in neutrophils. Blood. 2006; 108(13):4205-13. DOI: 10.1182/blood-2006-03-013789. View

14.

Sinha S, Yang W . Cellular signaling for activation of Rho GTPase Cdc42. Cell Signal. 2008; 20(11):1927-34. DOI: 10.1016/j.cellsig.2008.05.002. View

15.

Etienne-Manneville S, Hall A . Rho GTPases in cell biology. Nature. 2002; 420(6916):629-35. DOI: 10.1038/nature01148. View

16.

Vega F, Ridley A . Rho GTPases in cancer cell biology. FEBS Lett. 2008; 582(14):2093-101. DOI: 10.1016/j.febslet.2008.04.039. View

17.

Yang L, Wang L, Zheng Y . Gene targeting of Cdc42 and Cdc42GAP affirms the critical involvement of Cdc42 in filopodia induction, directed migration, and proliferation in primary mouse embryonic fibroblasts. Mol Biol Cell. 2006; 17(11):4675-85. PMC: 1635400. DOI: 10.1091/mbc.e06-05-0466. View